阿比特龙醋酸酯与多西他赛治疗转移性去势敏感性前列腺癌的成本效果分析:香港视角
本研究采用确定性马尔可夫模型,基于五项随机对照试验数据,从香港社会视角比较ADT+AA与ADT+D治疗转移性去势敏感性前列腺癌的成本效果。以三倍人均GDP(138,649美元)为支付意愿阈值,ADT+D在所有模拟中更具成本效果;ADT+AA仅在阿比特龙成本降低至少63%时才更具成本效果。低剂量AA(250 mg)策略在疗效等效时可能具有成本效果。
要点
- ADT+D相比ADT单药,ICER为14,397美元/QALY,具有成本效果。
- ADT+AA相比ADT+D,ICER为361,439美元/QALY,超过支付意愿阈值。
- ADT+AA需降价至少63%才比ADT+D更具成本效果。
核心结论
- 在发达经济体中,ADT+D比ADT+AA对转移性去势敏感性前列腺癌患者更具成本效果。
- 与D相比,加用AA可显著改善QALY,但成本显著增加。
研究设计与样本
- 采用确定性马尔可夫模型,模拟至死亡的成本效果。
- 生存曲线取自五项随机对照试验(CHAARTED、LATITUDE、两项STAMPEDE(2016/2017)和GETUG-AFU15)并数字化。
- 从香港社会视角,以三倍当地人均GDP(138,649美元)为支付意愿阈值。
- 主要结局为质量调整生命年(QALY)和增量成本效果比(ICER)。
主要发现
- 与ADT单药相比,ADT+D获得0.79(中位;95%可信区间0.56-0.97)QALY,ICER为14,397美元/QALY(7,824-22,632)。
- 与ADT+D相比,ADT+AA进一步获得0.79(0.45-1.17)QALY,但ICER为361,439美元/QALY(260,615-599,683)。
- 以三倍人均GDP为支付意愿阈值,ADT+D在所有模拟中更具成本效果;仅当阿比特龙成本降低至少63%时,ADT+AA才比ADT+D更具成本效果。
- 低剂量AA(250 mg)策略在产生与标准剂量(1000 mg)等效疗效时可能具有成本效果。
关键数值与推荐
- 支付意愿阈值为三倍当地人均GDP,即138,649美元。
- ADT+D相比ADT单药的ICER为14,397美元/QALY(95%可信区间7,824-22,632)。
- ADT+AA相比ADT+D的ICER为361,439美元/QALY(95%可信区间260,615-599,683)。
- ADT+AA比ADT+D更具成本效果的条件是阿比特龙成本降低至少63%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several randomized control trials (RCTs) have showed that adding either abiraterone acetate (AA) or docetaxel (D) to androgen-deprivation therapy (ADT) improves survival of metastatic castration-sensitive prostate cancer patients (mCSPC). Yet, the cost-effectiveness of these treatment options has not been fully compared under Hong Kong's setting. This cost-effectiveness analysis (CEA) serves as the first study in Hong Kong to compare the economic value of these two combinations ADT + AA vs. ADT + D. METHODS: A deterministic Markov model is used to project cost-effectiveness of each treatment until death. Survival curves for progression/death were extracted and digitized from the five RCTs (CHAARTED, LATITUDE, two STAMPEDE (2016/2017), and GETUG-AFU15). Clinically significant adverse events (AEs) were modeled; utility values were obtained from the literature. Primary outcomes were the quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER). We used the societal perspective from Hong Kong and considered three times of local gross domestic product per capita (GDPpc) as the willingness-to-pay (WTP) threshold (i.e., US$138,649). We estimated the break-even cost of AA in case ADT + AA is not a cost-effective strategy under this WTP threshold. While considering the standard AA dosage (1000 mg) as the main analysis, we also examined the potential impact of the low-dose AA (250 mg) strategy. RESULTS: Integrating simulations with probabilistic sensitivity analysis, ADT + D returns 0.79 (median; 95% credible interval 0.56-0.97) QALY with an ICER of US$14,397/QALY ($7824-22,632) compared to ADT-alone. A head-to-head comparison indicates that ADT + AA further gains 0.79 (0.45-1.17) QALY but with an ICER of $361,439/QALY ($260,615-599,683) when compared to ADT + D. Considering three times of GDPpc as WTP threshold, ADT + D is more cost-effective in all simulations; while ADT + AA is more cost-effective than ADT + D only if the cost of AA is reduced by at least 63%. The low-dose AA (250 mg) strategy is potentially cost-effective when it generates equivalent efficacy as the standard dosage (1000 mg). CONCLUSIONS: ADT + D is therefore shown to be a more cost-effective strategy than ADT + AA in metastatic castration-sensitive prostate cancer patients in developed economies. Addition of AA substantially improved QALY compared to D but at a significant cost.
引用
- Chiang CL, So TH, Lam TC, et al. Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective. Prostate Cancer Prostatic Dis. 2019. PMID: 31273290. doi:10.1038/s41391-019-0161-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。